- Home
- GAM vs AZTA Comparison
GAM vs AZTA Comparison
Compare GAM & AZTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAM
- AZTA
- Stock Information
- Founded
- GAM 1927
- AZTA 1978
- Country
- GAM United States
- AZTA United States
- Employees
- GAM N/A
- AZTA N/A
- Industry
- GAM Investment Managers
- AZTA Industrial Machinery/Components
- Sector
- GAM Finance
- AZTA Technology
- Exchange
- GAM Nasdaq
- AZTA Nasdaq
- Market Cap
- GAM 1.3B
- AZTA 1.4B
- IPO Year
- GAM N/A
- AZTA 1995
- Fundamental
- Price
- GAM $57.16
- AZTA $34.44
- Analyst Decision
- GAM
- AZTA Strong Buy
- Analyst Count
- GAM 0
- AZTA 5
- Target Price
- GAM N/A
- AZTA $41.20
- AVG Volume (30 Days)
- GAM 20.1K
- AZTA 529.3K
- Earning Date
- GAM 01-01-0001
- AZTA 11-21-2025
- Dividend Yield
- GAM 5.74%
- AZTA N/A
- EPS Growth
- GAM N/A
- AZTA N/A
- EPS
- GAM 11.67
- AZTA N/A
- Revenue
- GAM N/A
- AZTA $593,821,000.00
- Revenue This Year
- GAM N/A
- AZTA N/A
- Revenue Next Year
- GAM N/A
- AZTA $4.15
- P/E Ratio
- GAM $3.95
- AZTA N/A
- Revenue Growth
- GAM N/A
- AZTA N/A
- 52 Week Low
- GAM $37.32
- AZTA $23.91
- 52 Week High
- GAM $46.48
- AZTA $55.64
- Technical
- Relative Strength Index (RSI)
- GAM 23.84
- AZTA 69.42
- Support Level
- GAM $56.24
- AZTA $28.83
- Resistance Level
- GAM $58.22
- AZTA $30.18
- Average True Range (ATR)
- GAM 0.97
- AZTA 1.20
- MACD
- GAM -0.83
- AZTA 0.27
- Stochastic Oscillator
- GAM 8.58
- AZTA 88.24
About GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.
About AZTA Azenta Inc.
Azenta Inc is a provider of life sciences solutions, enabling impactful breakthroughs and therapies to market faster. It provides a full suite of reliable cold-chain sample management solutions and genomic services across areas such as drug development, clinical research and cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. The company has three reportable segments that are Sample Management Solutions, Multiomics, and B Medical Systems. It generates a substantial part of its revenue from its Sample Management Solutions segment.